NCT00189956

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: Bavarian Nordic · Industry
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The objective of the study is to find the optimal dose for the smallpox candidate vaccine IMVAMUNE (MVA-BN). For this purpose the study compares IMVAMUNE (MVA-BN) administered at three different dose levels.

Conditions

• Smallpox

Interventions

Type	Name	Description
BIOLOGICAL	IMVAMUNE (MVA-BN)	Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.

Timeline

• Start date: 2003-04-01
• Primary completion: 2003-11-01
• Completion: 2005-12-01
• First posted: 2005-09-19
• Last updated: 2019-01-10

Locations

1 site across 1 country: Switzerland